http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1230378-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9b442f17c57e6903e584b8486085ac9
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
filingDate 2000-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a279a97a025a6ec519a4cd9a848efc47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb7cb55dd8a9e99dde002ef042d7c935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f20704839d5d57603c7ecac266be7ed5
publicationDate 2002-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1230378-A2
titleOfInvention An oncolytic adenovirus
abstract Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11401529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077156-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11130968-B2
priorityDate 1999-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129062757
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3429
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11840927
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128334456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129713991
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61503
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226504276
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427744
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3604
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7895
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421272
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128280294

Total number of triples: 45.